Technology Offer

Method for the treatment of leukaemia - tergeted biological therapeutics

Summary

Czech academic institution developed a method for the treatment of leukaemia. The patented compounds have ability to inhibit specifically the cell cycle of cancer cells and therefore the active substance may be administered in smaller amounts than the competition, leading to a reduction in side effects. Institution seeks for a partner who would continue the preclinical stage of testing and potentially funded clinical stage. Research cooperation agreement is offered.

Expiration Date	13 February 2017
Reference	TOCZ20150623002
Profile link	

Details

Description

Czech academic institution developed a method for the treatment of leukaemia - targeted biological therapeutics (anti-leukemics). Longest-used method of treatment is chemotherapy, which is focused on the cellular structures that are common to all cells in the body. In addition to cancer cells and also acts on cells of other tissues, leading to the occurrence of many side effects. Second generation drugs invented by researchers are trying to find such molecules and processes that are specific to tumor cells (in cells normal tissues are either not present at all or only to a small extent) and develop drugs targeting these molecules and processes. Although even medication used for targeted therapies are accompanied by many undesirable effects, the incidence and severity of these effect becomes significant lower than in chemotherapy. Our inovation is based on pan-specific inhibition of protein kinases which is much more selective than previous generation grugs and our in vivo models shows much lower toxicity for normal tissues. Our molecules are effective in nano-molar concentrations and it is possibly allowing the use of very low doses of this biological drugs in the treatment of patients. Institution seeks for a partner who would continue the preclinical stage of testing and potentially funded clinical stage. Research cooperation agreement is offered.

Advantages and Innovations

Preliminary profiling suggested that the observed cellular selectivity of our compounds is tightly linked to specific mutations. Interestingly, these compounds also possess activity towards CDKs (Cyclin-dependent kinases) and we strongly believe that such dual specificity will be the key to truly effective AML (adult acute myeloid leukemia) therapy. Similar dual mechanisms of action have recently been described for two unrelated potent small molecule inhibitor. Our compounds display nanomolar IC50 values in MV4-11 cells, similar to sunitinib, dovitinib or TG02 .

Stage of Development

Under development/lab tested

Comments Regarding Stage of Development

Preclinical phase of development is completed.

IPR Status

Secret Know-how,Patent(s) applied for but not yet granted

Comment Regarding IPR status

The patent is in PCT (The Internation Patent System) stage, the coverage of the patent can be specified.

Keywords

Technology

06001002	Clinical Research, Trials
06001003	Cytology, Cancerology, Oncology
06001012	Medical Research

Market

04006	Cellular and Molecular Biology
05006	Anatomy, Pathology, Immunology, Physiology

NACE

M.72.1.1	Research and experimental development on biotechnology
Q.86.9.0	Other human health activities

Open for EOI : Yes

Client

Type and Size of Organisation Behind the Profile

R&D Institution

Year Established

1996

Client Country

Czech Republic

Partner Sought

Type and Role of Partner Sought

Institution seeks for a partner who would continue the preclinical stage of testing and potentially funded clinical stage. The research cooperation agreement is offered. The technology needs to be licenced to some pharmaceutical company, with knowledge how to develop the technology and possibly to get on market. We are able to provide information´s from preclinical phase and we would like to get our molecule to market.

Type of Partnership Considered

Research cooperation agreement

Technology Offer

New compounds (squaramide based) against Chagas and Leshmania

Summary

A multidisciplinary university research group has patented a new family of compounds with antiparasitic properties. These compounds are more stable, less toxic and cheaper to produce than the drugs currently used. Companies in the pharmaceutical or the veterinary sector interested in a patent license or in a research or technical cooperation agreement for developing and validating the product as antiparasitic are being sought.

Expiration Date 01 September 2017
Reference TOES20150706005
Profile link

Details

Description

Chagas and Leishmania diseases caused by protozoan parasites are a paradigmatic example of an extended parasitemia with unmet medical needs. Current treatments based on old-featured benznidazole and nifurtimox are expensive and do not fulfil the criteria of effectivity and lack of toxicity devoid to modern drugs.

As a result of the multidisciplinary cooperation between chemical and parasitologist researchers of two Spanish universities, a new family of aminosquaramide compounds with demonstrated in vivo activity against Chagas and Leshmania diseases has been developed. The chemical stability of these compounds together with the use of affordable starting products, and the lack of synthetic complexity put amino squaramides in the pole position toward the development of true low cost anti-parasitic agents.

The main application of the technology is a pharmaceutical composition for the treatment of human/animal parasitic diseases.

The researchers have determined the biological activity and the curative effects on murine models, but the next steps to be taken in the project are the hit to lead process, the target validation and the toxicological and ADME profile determination. Companies interested in advancing the project for developing the new antiparasitic product -through a licence or a research or technical cooperation agreement, are being sought.

Advantages and Innovations

The main advantages are their low toxicity in front of Vero cells and high effectivity ratios against the epimastigote and amastigote forms of the parasites. Also, the remarkable decrease (>97%) in the reactivation of parasitemia in the chronic phase after immunosuppression in mice and their chemical stability, affordable starting materials and straightforward synthesis.

Keywords

Technology

06001015	Pharmaceutical Products / Drugs
07001009	Veterinary Medicine

Market

02007012	Medical/health software
05009003	Animal health

NACE

C.21.1.0	Manufacture of basic pharmaceutical products

Open for EOI : Yes

Client

Type and Size of Organisation Behind the Profile

University

Year Established

0

Client Country

Spain

Partner Sought

Type and Role of Partner Sought

Company in the pharmaceutical area for parasitic diseases, for licensing the invention or interested in a research or technical cooperation agreement.

Type and Size of Partner Sought

SME 11-50,SME <10,>500 MNE,251-500,SME 51-250,>500

Type of Partnership Considered

License agreement
Technical cooperation agreement

Research cooperation agreement

Technology Request

Company based product incubator is looking for innovative healthcare concepts

Summary

A Czech SME active in pharmaceutical business is looking for inventors, universities and small companies with ideas of innovative medical devices, drugs and active ingredients. The Product incubator offers full range of services and necessary support to get innovative products to the market including an emphasis is on the testing phase. Partners for manufacturing agreement, technical cooperation agreement or licence agreement are sought.

Expiration Date 22 May 2017
Reference TRCZ20160517001
Profile link

Details

Description

The Czech SME has founded its incubator to promote the innovation process and technology transfer in the field of healthcare. The incubator offers practice and proven approach of successful pharmaceutical company and all the services under one roof which is unique in the context of European incubators.
The company has been involved in research, development and biotechnological production of active ingredients for the cosmetic and pharmaceutical industries for over twenty-five years. With an excellent production quality and extensive research facilities, it is one of the world's leading manufacturers of hyaluronic acid and its derived application. Its portfolio further includes various medical devices, veterinary drugs and nutrition supplements. Individual products are distributed to more than 50 countries worldwide.
The Product incubator provides a full range of services leading to the development of the innovative product. The laboratories are fully equipped, there are cleanrooms of different grades and pilot and manufacturing plants are certified for pharmaceutical production etc. The service includes finalizing of the research, pilot testing, manufacturing, planning, administration and evaluation of (pre)clinical testing, product certification and registration, and marketing and sales support with the opportunity to use the established distribution channels. All the activities are provided by experienced staff with deep knowledge of the field.

The individual inventors, university research teams, start-ups and spin-off, small companies etc. with ideas of innovative medical devices, drugs or active pharmaceutical or cosmetic ingredient are the main focus. The incoming innovative concept should be at least at TRL3 (Experimental Proof of Concept) and the partner should be dedicated to cooperation.

The Product incubator acts as an investor that is investing its service to develop the product. The role of the partner is highly variable and depends on their willingness to take risks and run their own business. Partners, who are interested in entrepreneurship, can take over the sales (or even production) and start building their own brand. Universities and research institution,

who are generally not willing to do business, can profit from royalty payments.

The role of the partner can be adjusted according to their needs. The Product Incubator is suitable for partners willing to run their own business based on manufacturing agreement or technical cooperation agreement as well as for partners, who are looking for a turnkey solution based on manufacturing agreement or license agreement in areas specified in "Expertise Sought" section.

Technical Specification or Expertise Sought

The Incubator is looking for inventors, spin-offs, start-ups and small companies specialized in:
- anti-ageing in cosmetics
- drug delivery systems
- electrospinning and related products
- fermentation products
- muscoskeletal diseases (osteoarthritis etc.)
- surgical materials (antiadhesives etc.)
- tissue engineering
- wound healing and regeneration

The preferred type of the finished product includes:
- active pharmaceutical ingredient
- active cosmetic ingredient
- drug (veterinary or human)
- medical device (veterinary or human)
- nutrition supplement (veterinary or human)

Keywords

Technology

03004011	Care, Hygiene, Beauty
06001015	Pharmaceutical Products / Drugs
06001024	Medical Biomaterials
06004	Micro- and Nanotechnology related to Biological sciences
06006004	Biopolymers

Market

04017	Micro- and Nanotechnology related to Biological sciences
05007002	Pharmaceuticals/fine chemicals
05007007	Other medical/health related (not elsewhere classified)
07004002	Health and beauty aids

NACE

C.21.1.0	Manufacture of basic pharmaceutical products
C.21.2.0	Manufacture of pharmaceutical preparations
G.46.4.5	Wholesale of perfume and cosmetics
G.46.4.6	Wholesale of pharmaceutical goods

Open for EOI : Yes

Client

Type and Size of Organisation Behind the Profile

Industry 250-499

Year Established

1990

Client Country

Czech Republic

Partner Sought

Type and Role of Partner Sought

All kinds of partners are welcome provided that they have highly innovative ideas and/or concepts of products in the field of veterinary and human pharmacy, medicine, healthcare and cosmetics.

The role of the partner can be adjusted according to their needs (see the description above). The Product Incubator is suitable for partners willing to run their own business - manufacturing or technical cooperation agreement; as well as for partners, who are looking for a turnkey solution - manufacturing or license agreement.

Type and Size of Partner Sought

SME 11-50,University,Inventor,R&D Institution,SME <10,SME 51-250

Type of Partnership Considered

License agreement
Manufacturing agreement
Technical cooperation agreement